Leukemia-free survival as a surrogate end point for overall survival in the evaluation of maintenance therapy for patients with acute myeloid leukemia in complete remission.
about
Center-Within-Trial Versus Trial-Level Evaluation of Surrogate EndpointsTime-dependent endpoints as predictors of overall survival in multiple myelomaEndpoints in advanced breast cancer: methodological aspects & clinical implications.NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance.Optimal therapy for adult patients with acute myeloid leukemia in first complete remission.Statistical evaluation of surrogate endpoints with examples from cancer clinical trials.Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer.An investigation into the two-stage meta-analytic copula modelling approach for evaluating time-to-event surrogate endpoints which comprise of one or more events of interest.Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors.Current Knowledge and Perspectives on Histamine H1 and H2 Receptor Pharmacology: Functional Selectivity, Receptor Crosstalk, and Repositioning of Classic Histaminergic Ligands.Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer.Impact of Copula Directional Specification on Multi-Trial Evaluation of Surrogate End Points.Mixed-phenotype acute leukemia: suboptimal treatment when the 2008/2016 WHO classification is used.Relationship between event-free survival and overall survival in acute myeloid leukemia: a report from SWOG, HOVON/SAKK, and MRC/NCRI.Evaluation of disease-free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trial-level meta-analysis.
P2860
Q30370596-3458319B-4A7C-4337-A4C5-A23A51F0CD62Q30538040-45E30191-1A4C-4D5B-A621-AE7A955F84CAQ35611036-7E0A185B-E074-4ADC-ACAA-43D4556BA1F6Q36618933-332BB40E-45CC-4583-AD9E-7169DAE576B3Q38208953-11A2C7CA-C83E-46DE-B627-6FD2A9FCEEBBQ38356102-DDC18E7D-A265-42A8-8DA8-28A6016C4BFFQ38630553-ACFF46B5-3279-4DE5-AA82-A406A34A62CFQ38763752-F4BA9882-0487-402A-8B25-7DF362937957Q38880510-545D9BD0-6AD5-4F74-91E5-2C4EB74C32A8Q38953768-9F832AFE-9029-4B37-8111-0C74F4F86C24Q39933767-16DF353B-AB2C-4E30-881D-B86D4B0DFE0EQ41865845-ED178B57-1358-4B50-84E8-D6D348CF0A31Q41945498-D0316FF6-572B-4D76-9174-C345CA4F1C00Q42399829-C015A382-E416-4E74-BF87-C8BE3D8EEA62Q47269814-211A3AC8-51AC-4465-9BE5-2317B53E0DAE
P2860
Leukemia-free survival as a surrogate end point for overall survival in the evaluation of maintenance therapy for patients with acute myeloid leukemia in complete remission.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Leukemia-free survival as a su ...... eukemia in complete remission.
@en
Leukemia-free survival as a su ...... eukemia in complete remission.
@nl
type
label
Leukemia-free survival as a su ...... eukemia in complete remission.
@en
Leukemia-free survival as a su ...... eukemia in complete remission.
@nl
prefLabel
Leukemia-free survival as a su ...... eukemia in complete remission.
@en
Leukemia-free survival as a su ...... eukemia in complete remission.
@nl
P2093
P2860
P1433
P1476
Leukemia-free survival as a su ...... leukemia in complete remission
@en
P2093
Jacob M Rowe
Kathryn J Lucchesi
Marc Buyse
Mats L Brune
Pierre Squifflet
Sylvie Castaigne
P2860
P304
P356
10.3324/HAEMATOL.2010.039131
P577
2011-05-05T00:00:00Z